APOE and Alzheimer disease: However, the therapeutic effects of RXR agonists, especially bexarotene, varied widely in follow-up studies (13, 14, 15, 16), suggesting that there is an unknown pathological factor causing this variation, and that the regulatory mechanism of RXR-ApoE needs to be elucidated to develop effective AD treatments.